MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. MabThera attacks these cells both directly and together with the body’s immune system.
MabThera SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of MabThera to be rapidly dispersed and absorbed over a greater area.
In the United States, Europe and in many other countries, MabThera SC is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
In the United States, MabThera SC is marketed as Rituxan Hycela.